Abbot Financial Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Abbot Financial Management’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-452,345	Closed	-$196K	–	117
2022 Q3	$196K	Sell	452,345 -956,000	-68%	-$717K	0.14%	107
2022 Q2	$1.2M	Hold	1,408,345	–	–	0.72%	43
2022 Q1	$7.76M	Sell	1,408,345 -2,660	-0.2%	-$16.9K	3.79%	3
2021 Q4	$13.7M	Sell	1,411,005 -770	-0.1%	-$10.7K	6.1%	2
2021 Q3	$25.2M	Hold	1,411,775	–	–	11.48%	1
2021 Q2	$34.5M	Sell	1,411,775 -2,725	-0.2%	-$68.2K	15.06%	1
2021 Q1	$37.5M	Buy	1,414,500 +877,500	+163%	+$12.8M	17.01%	1
2020 Q4	$4.08M	Sell	537,000 -26,500	-5%	-$157K	2.35%	6
2020 Q3	$2.82M	Hold	563,500	–	–	1.83%	16
2020 Q2	$3.37M	Hold	563,500	–	–	2.32%	7
2020 Q1	$2.51M	Hold	563,500	–	–	2.04%	12
2019 Q4	$5.35M	Buy	+563,500	New	+$5.45M	3.39%	4

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Abbot Financial Management's RUBY Position: Q4 2022 in Review

Abbot Financial Management sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 452,345 shares — an estimated $196K sold.

Abbot Financial Management first reported a position in RUBY in Q4 2019 and held it in 12 quarters. The position peaked at $37.5M in Q1 2021. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

Abbot Financial Management reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
Abbot Financial Management sold 452,345 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $196K.
Abbot Financial Management first reported a position in Rubius Therapeutics, Inc in Q4 2019 and held it in 12 quarters.
Abbot Financial Management's Rubius Therapeutics, Inc position peaked at $37.5M in Q1 2021.
42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on Abbot Financial Management's 13F filing for Q4 2022, filed 9 Feb 2023.